Patients receiving platinum-based chemotherapy and atezolizumab had significantly improved OS, with a median of 12.6 months compared to 9.7 months in NSCLC, and higher PD-L1 tumor cell expression as well as higher tumor filtration cell expression observed in in patients receiving docetaxel. This evidence concerns the gene CD274 and neoplasm.